Journal of Neuroimmunology
Volume 171, Issue 1 , Pages 8-16 , February 2006

Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice

  • Minako Oshima

      Affiliations

    • Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 798 6387; fax: +1 713 798 6437.
    • These authors contributed equally.
    • ,
  • Takahiro Maruta

      Affiliations

    • Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • These authors contributed equally.
    • ,
  • Maki Ohtani

      Affiliations

    • Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • ,
  • Philip R. Deitiker

      Affiliations

    • Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • ,
  • DennisR. Mosier

      Affiliations

    • Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • Neurology and Medical Research Services, M.E. DeBakey V.A. Medical Center, Houston, TX 77030, USA
    • ,
  • M. Zouhair Atassi

      Affiliations

    • Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • Department of Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

Received 4 May 2005 ,Revised 15 August 2005 ,Accepted 9 September 2005.

References 

  1. Atassi MZ, Oshima M. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. Crit. Rev. Immunol. 1997;17:481–495
  2. Atassi MZ, Ruan KH, Jinnai K, Oshima M, Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc. Natl. Acad. Sci. U. S. A. 1992;89:5852–5856
  3. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today. 1993;14:281–284
  4. Bellone M, Ostlie N, Lei S, Wu XD, Conti-Tronconi BM. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 1991;147:1484–1491
  5. Berman PW, Patrick J. Experimental myasthenia gravis. A murine system. J. Exp. Med. 1980;151:204–223
  6. Berrih-Aknin S, Cohen-Kaminsky S, Neumann D, Safar D, Eymard B, Gaud C, et al. Cellular aspects of myasthenia gravis. Immunol. Res. 1988;7:189–199
  7. Boughton CR. Pertussis vaccines: acellular versus whole-cell. Med. J. Aust. 1996;164:564–566
  8. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993;364:33–39
  9. Bugawan TL, Angelini G, Larrick J, Auricchio S, Ferrarar GB, Erlich HA. A combination of a particular HLA-DP β allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease. Nature. 1989;339:470–473
  10. Christadoss P, Lennon VA, Krco CJ, David CS. Genetic control of experimental autoimmune myasthenia gravis in mice: III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors. J. Immunol. 1982;128:1141–1144
  11. Christadoss P, Lindstrom JM, Melvold RW, Talal N. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 1985;21:33–38
  12. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology. 1990;40:786–790
  13. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U. S. A. 1992;89:358–362
  14. Harlow E, Lane D. In: Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory; 1988;p. 99
  15. Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, et al. Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis. J. Neuroimmunol. 1996;65:125–131
  16. Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka KV. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology. 1986;36:618–621
  17. Hohlfeld R, Toyka KV, Tzartoss SJ, Carson W, Conti-Tronconi B. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit. Proc. Natl. Acad. Sci. U. S. A. 1987;84:5379–5383
  18. Horiki T, Inoko H, Moriuchi J, Ichikawa Y, Arimori S. Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity. 1994;19:49–54
  19. Infante AJ, Thompson PA, Krolick KA, Wall KA. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J. Immunol. 1991;146:2977–2982
  20. Johns TR. Long-term corticosteroid treatment of myasthenia gravis. Ann. N.Y. Acad. Sci. 1987;505:568–583
  21. Kahn CR, McIntosh KR, Drachman DB. T-cell vaccination in experimental myasthenia gravis: a double-edged sword. J. Autoimmun. 1990;3:659–669
  22. Kanai T, Nomura Y, Segawa M, Takagi K, Senju S, Matsushita S, et al. Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by the disease-susceptible HLA-DQ6 in infant-onset myasthenia gravis. Hum. Immunol. 1997;56:28–38
  23. Karachunski PI, Ostlie NS, Okita DK, Conti-Fine BM. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 1997;100:3027–3035
  24. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 1999;163:4481–4488
  25. Lennon VA, McCormick DJ, Lambert EH, Griesmann GE, Atassi MZ. Region of peptide 125–147 of acetylcholine receptor of α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc. Natl. Acad. Sci. U. S. A. 1985;82:8805–8809
  26. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–1059
  27. McAnally JL, Xu L, Villain M, Blalock JE. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Exp. Biol. Med. 2001;226:307–311
  28. McCormick DJ, Atassi MZ. Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor. Biochem. J. 1984;224:995–1000
  29. McIntyre KR, Seidman JG. Nucleotide sequence of mutant I-Aβbm12 gene is evidence for genetic exchange between mouse immune response genes. Nature. 1984;308:551–553
  30. Nagvekar N, Corlett L, Jacobson LW, Matsuo H, Chalkley R, Driscoll PC, et al. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 1999;162:4079–4087
  31. Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J. Neuroimmunol. 2000;105:131–144
  32. Ofosu-Appiah W, Mokhtarian F, Shirazian D, Grob D. Production of anti-acetylcholine receptor-α antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes. J. Lab. Clin. Med. 1994;124:231–241
  33. Oshima M, Atassi MZ. Effect of amino acid substitutions within the region 62–76 of I-Aβb on binding with and antigen presentation of Torpedo acetylcholine receptor α chain peptide 146–162. J. Immunol. 1995;154:5245–5254
  34. Oshima M, Pachner AR, Atassi MZ. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol. Immunol. 1994;31:833–843
  35. Oshima M, Deitiker P, Ashizawa T, Atassi MZ. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity. 2002;35:183–190
  36. Oshima M, Ohtani M, Deitiker PR, Smith RG, Mosier DR, Atassi MZ. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity. 2005;38:161–169
  37. Pachner AR, Kantor FS, Mulac-Jericevic B, Atassi MZ. An immunodominant site of acetylcholine receptor in experimental myasthenia gravis mapped with T-lymphocyte clones and synthetic peptides. Immunol. Lett. 1989;20:199–204
  38. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003;61:1652–1661
  39. Rickman LS, Gordon DM, Wistar R, Krzych U, Gross M, Hollingdale MR, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991;337:998–1001
  40. Rosenberg JS, Oshima M, Atassi MZ. B-cell activation in vitro by helper T cells specific to region α146–162 of Torpedo californica nicotinic acetylcholine receptor. J. Immunol. 1996;157:3192–3199
  41. Shenoy M, Oshima M, Atassi MZ, Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146–162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 1993;66:230–238
  42. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368:215–221
  43. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II-associated autoimmunity. Science. 1988;240:1003–1009
  44. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev., Immunol. 2002;2:797–804
  45. Yokoi T, Mulac-Jericevic B, Kurisaki J, Atassi MZ. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 1987;17:1697–1702
  46. Yoshikawa H, Iwasa K, Satoh K, Takamori M. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J. Autoimmun. 1997;10:11–16

PII: S0165-5728(05)00422-4

doi: 10.1016/j.jneuroim.2005.09.015

Journal of Neuroimmunology
Volume 171, Issue 1 , Pages 8-16 , February 2006

Article Tools

* Image Usage & Resolution